| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 1.11 [0.85, 1.47] | | < 1 | | 85% | 5 studies (5/-) | 22.0 % | low | not evaluable | high | crucial | - |
| progression or deaths (PFS) | 1.53 [1.20, 1.95] | | < 1 | | 67% | 3 studies (3/-) | 0.0 % | some concern | not evaluable | moderate | important | - |
| DCR | 0.84 [0.61, 1.16] | | > 1 | | 0% | 1 study (1/-) | 14.4 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 0.82 [0.34, 1.96] | | > 1 | | 92% | 5 studies (5/-) | 32.8 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.69 [0.27, 1.78] | | < 1 | | 0% | 2 studies (2/-) | 77.9 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 0.99 [0.73, 1.34] | | < 1 | | 0% | 2 studies (2/-) | 53.1 % | low | not evaluable | high | non important | - |
| TRAE (any grade) | 0.64 [0.45, 0.90] | | < 1 | | 69% | 5 studies (5/-) | 99.5 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 0.90 [0.52, 1.54] | | < 1 | | 84% | 5 studies (5/-) | 65.4 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 0.56 [0.14, 2.32] | | < 1 | | 0% | 3 studies (3/-) | 78.7 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 0.78 [0.44, 1.39] | | < 1 | | 74% | 3 studies (3/-) | 79.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 0.45 [0.30, 0.66] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 0.70 [0.10, 5.04] | | < 1 | | 0% | 3 studies (3/-) | 64.0 % | low | not evaluable | high | non important | - |
| Colitis TRAE (grade 3-4) | 2.17 [0.78, 6.04] | | < 1 | | 77% | 5 studies (5/-) | 6.9 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.22 [0.59, 2.51] | | < 1 | | 56% | 5 studies (5/-) | 29.9 % | low | serious | high | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 1.92 [0.29, 12.94] | | < 1 | | 80% | 3 studies (3/-) | 25.2 % | low | not evaluable | high | non important | - |
| Eye disorders TRAE (grade 3-4) | 2.01 [0.07, 60.22] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.25 [0.01, 5.57] | | < 1 | | 0% | 1 study (1/-) | 80.6 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 1.36 [0.42, 4.35] | | < 1 | | 80% | 3 studies (3/-) | 30.5 % | low | not evaluable | high | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 0.25 [0.01, 5.57] | | < 1 | | 0% | 1 study (1/-) | 80.6 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 0.41 [0.14, 1.15] | | < 1 | | 0% | 5 studies (5/-) | 95.6 % | low | not evaluable | high | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 0.25 [0.03, 2.01] | | < 1 | | 0% | 2 studies (2/-) | 90.3 % | low | not evaluable | high | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 0.17 [0.01, 3.33] | | < 1 | | 0% | 1 study (1/-) | 87.7 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.22 [0.56, 2.63] | | < 1 | | 0% | 5 studies (5/-) | 30.8 % | low | serious | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.83 [0.17, 4.10] | | < 1 | | 0% | 5 studies (5/-) | 59.3 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 0.86 [0.21, 3.56] | | < 1 | | 21% | 5 studies (5/-) | 58.1 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.71 [0.18, 2.78] | | < 1 | | 29% | 5 studies (5/-) | 68.7 % | low | not evaluable | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 0.50 [0.02, 15.01] | | < 1 | | 0% | 1 study (1/-) | 65.2 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.25 [0.01, 5.57] | | < 1 | | 0% | 1 study (1/-) | 80.6 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.06 [0.17, 6.53] | | < 1 | | 0% | 3 studies (3/-) | 47.5 % | some concern | not evaluable | moderate | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 0.12 [0.01, 2.36] | | < 1 | | 0% | 1 study (1/-) | 91.5 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.50 [0.02, 15.01] | | < 1 | | 0% | 1 study (1/-) | 65.2 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.50 [0.02, 15.01] | | < 1 | | 0% | 1 study (1/-) | 65.2 % | NA | not evaluable | | non important | - |
| Pericarditis TRAE (grade 3-4) | 0.50 [0.02, 15.01] | | < 1 | | 0% | 1 study (1/-) | 65.2 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.25 [0.01, 5.57] | | < 1 | | 0% | 1 study (1/-) | 80.6 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.61 [0.11, 3.47] | | < 1 | | 0% | 3 studies (3/-) | 71.0 % | some concern | not evaluable | moderate | non important | - |
| Polymyalgia Rheumatica TRAE (grade 3-4) | 2.01 [0.07, 60.22] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Pruritic rash TRAE (grade 3-4) | 1.39 [0.16, 11.91] | | < 1 | | 0% | 3 studies (3/-) | 38.3 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 1.09 [0.28, 4.24] | | < 1 | | 0% | 5 studies (5/-) | 45.3 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 0.62 [0.20, 1.89] | | < 1 | | 0% | 5 studies (5/-) | 80.1 % | low | serious | high | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 0.12 [0.01, 2.36] | | < 1 | | 0% | 1 study (1/-) | 91.5 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 0.79 [0.33, 1.93] | | < 1 | | 0% | 3 studies (3/-) | 69.5 % | low | not evaluable | high | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.50 [0.02, 15.01] | | < 1 | | 0% | 1 study (1/-) | 65.2 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 1.39 [0.16, 11.91] | | < 1 | | 0% | 3 studies (3/-) | 38.3 % | some concern | not evaluable | moderate | non important | - |
| Vitiligo TRAE (grade 3-4) | 1.71 [0.11, 27.50] | | < 1 | | 0% | 2 studies (2/-) | 35.3 % | low | not evaluable | high | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.51 [0.15, 1.75] | | < 1 | | 15% | 2 studies (2/-) | 85.6 % | low | not evaluable | high | non important | - |
| Anaemia AE (grade 3-4) | 0.61 [0.20, 1.81] | | < 1 | | 43% | 2 studies (2/-) | 81.5 % | low | not evaluable | high | non important | - |
| Constipation AE (grade 3-4) | 2.99 [0.80, 11.14] | | < 1 | | 0% | 2 studies (2/-) | 5.2 % | low | not evaluable | high | non important | - |
| Cough AE (grade 3-4) | 1.24 [0.09, 16.24] | | < 1 | | 0% | 2 studies (2/-) | 43.5 % | low | not evaluable | high | non important | - |
| Decreased appetite AE (grade 3-4) | 0.71 [0.22, 2.29] | | < 1 | | 0% | 2 studies (2/-) | 71.8 % | low | not evaluable | high | non important | - |
| Diarrhoea AE (grade 3-4) | 2.30 [0.42, 12.63] | | < 1 | | 58% | 2 studies (2/-) | 17.0 % | low | not evaluable | high | non important | - |
| Dyspnoea AE (grade 3-4) | 0.95 [0.43, 2.08] | | < 1 | | 0% | 2 studies (2/-) | 55.5 % | low | not evaluable | high | non important | - |
| Fatigue AE (grade 3-4) | 1.65 [0.84, 3.25] | | < 1 | | 0% | 2 studies (2/-) | 7.3 % | low | not evaluable | high | non important | - |
| Headache AE (grade 3-4) | 1.53 [0.51, 4.62] | | < 1 | | 0% | 2 studies (2/-) | 22.5 % | low | not evaluable | high | non important | - |
| Nausea AE (grade 3-4) | 1.25 [0.43, 3.59] | | < 1 | | 0% | 2 studies (2/-) | 34.2 % | low | not evaluable | high | non important | - |
| Pyrexia AE (grade 3-4) | 0.42 [0.05, 3.82] | | < 1 | | 0% | 2 studies (2/-) | 77.6 % | low | not evaluable | high | non important | - |
| Vomiting AE (grade 3-4) | 1.14 [0.40, 3.25] | | < 1 | | 0% | 2 studies (2/-) | 40.2 % | low | not evaluable | high | non important | - |
